mepivacaine and Skin Aging

mepivacaine has been researched along with Skin Aging in 2 studies

Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.

Skin Aging: The process of aging due to changes in the structure and elasticity of the skin over time. It may be a part of physiological aging or it may be due to the effects of ultraviolet radiation, usually through exposure to sunlight.

Research

Studies (2)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Non-inferiority of RHA® Redensity With New Anesthetic Agent Versus RHA® Redensity With Lidocaine in Terms of Reducing Pain During Device Injection Into the Upper Perioral Rhytids.

"Injection pain during injection was measured on the 100 mm Visual Analog Scale (VAS), as assessed by subjects immediately after injection of each upper perioral quadrant.~VAS is a 100 mm Visual Analog Scale with 0 meaning no pain and 100 meaning intolerable pain" (NCT04069585)
Timeframe: Visit 1 - During Injection

"Number of Global Aesthetic Improvement (GAI) Responders (i.e., Scoring Either Much Improved or Improved) on GAI Scale According to Subject's Self-assessment"

"Global Aesthetic Improvement (GAI) is a subjective 5-grade scale comprised of much improved, improved, no change, worse, and much worse.~GAI was assessed using the baseline photograph. Subjects were instructed as follows: Use a mirror to compare your face to the photograph provided to you and rate the degree of aesthetic improvement by using the following scale.~Each side of the face was assessed independently." (NCT04069585)
Timeframe: Visit 1 (post-injection) and Visit 2 (Day 30)

"Number of Subjects Scored Either Much Improved or Improved on Global Aesthetic Improvement (GAI) by the Treating Investigator (TI)"

"Global Aesthetic Improvement (GAI) is a subjective 5-grade scale comprised of much improved, improved, no change, worse, and much worse.~GAI will bewas assessed using the baseline photograph. Each side of the mouth were assessed independently." (NCT04069585)
Timeframe: Visit 1 (post-injection) and Visit 2 (Day 30)

Change From Baseline of PR-SRS Score for RHA® Redensity With New Anesthetic Agent Vs RHA® Redensity With Lidocaine for the Correction of Perioral Rhytids as Assessed by the Treating Investigator (TI)

"PR-SRS (Perioral Rhytids Severity Rating Scale) is a validated 4-grade scale with 0 being Absent and 3 being Severe" (NCT04069585)
Timeframe: Visit 1 (Baseline, pre-injection) - Visit 1 (post-injection), Visit 2 (Day 30)

Difference Between RHA® Redensity With New Anesthetic Agent Versus RHA® Redensity With Lidocaine in Term of Reducing Pain at 15, 30, 45 and 60 Minutes Post-injection in Each Side of the Mouth.

"Injection pain was measured on the 100 mm Visual Analog Scale (VAS), as assessed by subjects in each side of the mouth.~VAS is a 100 mm Visual Analog Scale with 0 meaning no pain and 100 meaning intolerable pain" (NCT04069585)
Timeframe: Visit 1 - 15, 30, 45 and 60 minutes post-injection

Number of Subjects With Post Injection Treatment Responses (From Common Treatment Responses (CTR) Diary) for Safety Evaluation of RHA® Redensity With New Anesthetic Agent Versus RHA® Redensity With Lidocaine

"The subjects will receive a diary booklet and instructions for recording his/her observations of the Common Treatment Responses to the study treatments within 30 days following the treatment. The diary will be discussed during follow-up phone-call and visit. Subjects were instructed to complete the diary at approximately the same time each day (i.e., am or pm).~The subject diary captured the following Common Treatment Responses (CTR) that occur following the injection of a dermal filler; specifically, redness, pain, tenderness, firmness, swelling, lumps/bumps, bruising, itching, discoloration, and other.~The 30-day patient CTR diary included a detailed glossary describing all signs/symptoms listed in the diary; an option was provided to report other reactions if the subject experienced a sign/symptom that was not listed." (NCT04069585)
Timeframe: During 30 days after injection

Subject's Perception of Treatment Effectiveness as Per the FACE-Q (Perioral Rhytids Domain) Questionnaire.

"The FACE-Q measures the experience and outcomes of aesthetic facial procedures from the patient's perspective.~FACE-Q questionnaire is composed of 6 questions with a score linked to answers (1 being 'Not at all' and 4 being 'Extremely').~The subject will be instructed as follows: These questions ask about how you look right now. For each question, circle only one answer. With the area around your lips in mind, in the past week, how much have you been bothered by:, and will provide response.~To calculate the FACE-Q, outcomes from all 6 questions were pooled, data were transformed so that higher scores reflected a superior outcome, and adapted to a scale of 100 units (i.e. lowest score = 0, highest score = 100)." (NCT04069585)
Timeframe: Visit 1 (Baseline) and Visit 2 (Day 30)

"Number of Both Satisfied or Very Satisfied Subjects With Study Treatment Using the Subject's Satisfaction Scale"

"The Subject Satisfaction Scale is a subjective, balanced, 5-point scale assessing subject satisfaction with study treatment. Possible scores range from with 1 (very satisfied) to 5 (very dissatisfied).~Proportion of subjects who were Satisfied (i.e., 1-Very Satisfied + 2-Satisfied) was compared to the proportion of subjects who were Not Satisfied (i.e., 3-Neither Satisfied nor dissatisfied + 4-Dissatisfied + 5-Very Dissatisfied)" (NCT04069585)
Timeframe: Visit 1 (post-injection) and Visit 2 (Day 30)

Percentage of Responders Based on the Intra-individual Improvement of at Least One Grade on the Perioral Rhytids Severity Rating Scale (PR-SRS) Compared to Baseline, as Assessed by the TI

A responder corresponds to a subject with an intra-individual improvement of at least one grade on the PR-SRS compared to Baseline (NCT04069585)
Timeframe: Visit 1 - Baseline (pre-injection), Visit 1 (post-injection), Visit 2 (Day 30)

Trials

2 trials available for mepivacaine and Skin Aging